Several studies have investigated the use of simple in vitro tests for the assessment of rabies antibody titers in serum samples from vaccinated human subjects, which would allow the effectiveness of rabies vaccination to be conveniently evaluated. To this end, a novel time-resolved fluoroimmunoassay (TRFIA) for the assessment of rabies antibody titers was established in this study for evaluating the effectiveness of protection against rabies. The TRFIA had a satisfactory limit of detection value (0.035 IU/mL) under optimal conditions. Additionally, the application of the TRFIA was demonstrated in 68 serum samples with satisfactory results. The coefficient variations (CVs) were all <10%, and the recoveries were in the range of 90–110%. The correlation coefficient of titer values obtained using the present TRFIA and the rapid fluorescent focus inhibition test (RFFIT) was 0.733, with a coincidence rate regarding the evaluation results (protected or not protected by vaccination) of 100%. The preliminary results confirmed that the TRFIA had a higher performance than an enzyme-linked immunosorbent assay (ELISA), and could potentially replace the ELISA. Based on these results, the novel TRFIA appears to be a convenient tool for the evaluation of rabies vaccination results based on serum samples from vaccinated human subjects.

几项研究调查了使用简单的体外测试评估接种人类受试者血清样本中狂犬病抗体滴度的情况，这将允许方便地评估狂犬病疫苗接种的有效性。为此，本研究建立了一种用于评估狂犬病抗体效价的新型时间分辨荧光免疫分析 (TRFIA)，以评估预防狂犬病的有效性。TRFIA 在最佳条件下具有令人满意的检测限 (0.035 IU/mL)。此外，TRFIA 在 68 份血清样本中的应用得到了令人满意的结果。系数变化 (CV) 均 <10%，回收率在 90-110% 的范围内。使用本TRFIA和快速荧光病灶抑制试验（RFFIT）获得的滴度值的相关系数为0.733，评价结果（接种保护或未保护）的符合率为100%。初步结果证实，TRFIA 比酶联免疫吸附测定 (ELISA) 具有更高的性能，并有可能取代 ELISA。基于这些结果，新的 TRFIA 似乎是评估狂犬病疫苗接种结果的便捷工具，该工具基于接种人类受试者的血清样本。初步结果证实，TRFIA 比酶联免疫吸附测定 (ELISA) 具有更高的性能，并有可能取代 ELISA。基于这些结果，新的 TRFIA 似乎是评估狂犬病疫苗接种结果的便捷工具，该工具基于接种人类受试者的血清样本。初步结果证实，TRFIA 比酶联免疫吸附测定 (ELISA) 具有更高的性能，并有可能取代 ELISA。基于这些结果，新的 TRFIA 似乎是评估狂犬病疫苗接种结果的便捷工具，该工具基于接种人类受试者的血清样本。